FindTrial
Sign In

Evaluating the benefits of beta glucan in duchenne muscular dystrophy patients

Linear study to evaluate the efficacy and safety of beta 1 3-1 6 glucan in patients with duchenne muscular dystrophy - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/085825
Enrollment
100
Registered
2025-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M638- Disorders of muscle in diseases classified elsewhere

Interventions

Intervention1: Beta-1 3-1 6-glucan: Dose: Food Supplement Administration: Twice a day Route: Oral Treatment duration: 1 year Control Intervention1: Nil: Nil

Sponsors

Muthulakshimi Kadalraja Health educational Empowerment Research Charitable Trust
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male patients diagnosed with DMD Age between 3 years and 30 years Willingness to participate and provide written informed consent Ability and willingness to comply with the study protocol

Exclusion criteria

Exclusion criteria: Participation in another clinical trial in the last 30 days Failure to provide informed consent by the subject or legally authorized representative Presence of any severe comorbid condition that may interfere with the study objectives

Design outcomes

Primary

MeasureTime frame
To observe muscle strength improvement through physiotherapy assessmentTimepoint: 12 months—

Secondary

MeasureTime frame
To monitor inflammatory and cytokinesTimepoint: 12 months—

Countries

India

Contacts

Public ContactRAJENDRA SUNDARAM

RK Maples Hospital

drkraghavan27@gmail.com09840301991

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026